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OBJECTIVE — To evaluate the efﬁcacy and safety of actovegin in patients with diabetic
polyneuropathy.
RESEARCH DESIGN AND METHODS — In this multicenter, randomized, double-
blind trial, 567 patients with type 2 diabetes received 20 intravenous infusions of actovegin
(2,000mg/day)(n281)orplacebo(n286)oncedailyfollowedbythreetabletsofactovegin
(1,800mg/day)orplacebothreetimesdailyfor140days.Totalsymptomscore(TSS)ofthelower
limbs and vibration perception threshold (VPT) were used as coprimary outcome measures,
computed as the area under the curve (AUC) from repeated scores and divided by duration of
exposure. Secondary end points included individual TSS symptoms, neuropathy impairment
score of the lower limbs (NIS-LL), and quality of life (short form [SF]-36).
RESULTS — TSS was signiﬁcantly improved during actovegin treatment compared with pla-
cebo, as assessed by AUC (0.56 points [95% CI 0.85 to 0.27]; P  0.0003), and from
baseline to 160 days (0.86 points [1.22 to 0.50]; P  0.0001). VPT (ﬁve sites per foot)
decreasedby3%(95%CI0–6;P0.084)withactoveginthanplacebo,asassessedbyAUC,and
by 5% (1–9; P  0.017) after 160 days. NIS-LL sensory function, as assessed by AUC, was
signiﬁcantly improved with actovegin versus placebo (0.25 [95% CI 0.46 to 0.04]; P 
0.021), as was the SF-36 mental health domain. There were no differences in the incidence of
adverse events between the groups.
CONCLUSIONS — Sequential intravenous and oral actovegin treatment over 160 days im-
proved neuropathic symptoms, VPT, sensory function, and quality of life in type 2 diabetic
patients with symptomatic polyneuropathy.
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D
iabetic distal symmetric polyneu-
ropathy (DPN) affects approxi-
mately one-third of patients with
diabetes (1) and is responsible for sub-
stantial morbidity, being associated with
excruciating neuropathic pain and foot
ulcers leading to amputation (2). Neuro-
pathic pain may affect up to 26% of the
diabetic population (3) and can exert a
substantial impact on quality of life, par-
ticularly through the impairment of sleep
andreducedenjoymentoflife(4).Several
classes of analgesics are effective in the
treatment of neuropathic pain, but no
more than 40–60% of patients show ad-
equate pain relief on monotherapy (5).
Moreover, these drugs are frequently as-
sociated with central nervous system side
effects and do not slow the progression of
the underlying neuropathy (2). Based on
thepathogeneticmechanismsofDPN(6),
several therapeutic approaches have been
developed(2,7,8).Thesedrugshavebeen
designed to favorably inﬂuence the
pathophysiology of the disorder rather
than simply relieve pain. However, de-
spiteapparentrecentprogress,thepharma-
cologic treatment of chronic symptomatic
DPN remains a challenge for the physi-
cian (5).
Actovegin is a deproteinized hemod-
erivative produced from calf blood by ul-
traﬁltration that contains low–molecular
weight compounds of up to 5,000 Da.
Oxygen absorption, oxygen utilization,
and cellular energy metabolism are stim-
ulated by actovegin (9). Furthermore, ac-
tovegin exerts insulin-like activity, such
as stimulation of glucose transport, pyru-
vate dehydrogenase, and glucose oxida-
tion (10,11). Because of these properties,
actovegin has previously been used for
treatment of cerebral vascular and degen-
erative disorders (12,13). In a previous
small trial (14), actovegin was shown to
improve nerve conduction velocity, allo-
dynia, and subjective well-being after 24
weeks in patients with DPN.
Evidence has emerged to suggest that
nerve ischemia and hypoxia appear to
playaparamountroleinthepathogenesis
of DPN. Reduced nerve blood ﬂow in ex-
perimental DPN may be prevented and
corrected by several disease-modifying
drugs (6). Against this background, we
conducted a randomized, controlled trial
to evaluate the efﬁcacy and safety of se-
quential treatment using 20 intravenous
infusions of actovegin (2,000 mg) once
daily followed by oral administration
(1,800 mg/day) for 140 days.
RESEARCH DESIGN AND
METHODS— This was a multicenter
(26 centers, three countries), random-
ized, double-blind, placebo-controlled,
parallel-group clinical trial (AV-007-IM).
Patients were followed for 6 months
from the screening visit to the end of the
oral treatment period, with efﬁcacy as-
sessments at screening, at every ﬁfth infu-
sion visit, and every 4 weeks during the
oral treatment period. Adverse events
(AEs) were assessed at all visits. Approval
was obtained from local ethics commit-
tees, and all patients provided written in-
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screening period of 5 days, a total of 569
type2diabeticpatientswithsymptomatic
diabetic peripheral polyneuropathy were
randomly assigned via an interactive
voice response service to treatment with
either actovegin (Nycomed Austria) or
placebo. To homogenize the study popu-
lation, the randomization procedure was
stratiﬁed according to site and the pres-
ence or absence of insulin treatment.
Treatment consisted of 20 once-daily
intravenous infusions (actovegin 20%
with 8 mg/ml or placebo in 250 ml so-
dium chloride 0.9%; infusion rate: 2 ml/
min) for 20–36 days, followed by three
tablets (200 mg actovegin per coated tab-
let or placebo) three times daily for 140
days, with a permitted variation of 125–
155 days. In the intention-to-treat (ITT)
population,themedian(range)periodsof
intravenous and oral treatment were 25
days (1–38) and 146 days (17–169) for
actovegin and 25 days (1–37) and 146
days (10–169) for placebo, respectively.
All bottles containing solution for in-
fusion (active and placebo) were identical
and had a nontransparent plastic cover,
while tubes for infusion were manufac-
tured in colored plastic material. Before
blinding (i.e., before application of the
plastic cover), the bottles were stored for
3 months and the solution was checked
visually for foreign bodies. The coated
tablets(activeandplacebo)wereidentical
in size and appearance.
Inclusion criteria were age between
18 and 65 years; type 2 diabetes accord-
ing to the American Diabetes Association
criteria (15); evidence of symptomatic
DPN (i.e., total symptom score [TSS] 6
and neuropathy impairment score of the
lower limbs [NIS-LL] 2, vibration per-
ception threshold [VPT] 30 volts, and
palpable pulses of posterior tibial artery
anddorsalarteryofthefoot);A1C10%;
patient able to meet the center visits over
thetrialperiod;stabledoseoftricyclican-
tidepressants, anticonvulsants, mexil-
etine,orneurolepticsinpatientsreceiving
these drugs for neuropathic pain within
the last month; acceptable contraceptive
method (hormonal pills, patches, im-
plants, injections, or intrauterine device)
in female patients of childbearing poten-
tial; and a negative pregnancy test before
the ﬁrst dose of trial medication.
Exclusioncriteriaincludedknownal-
lergy to actovegin or similar preparations;
asymmetrical neuropathy of the trunk or
proximal lower limbs; foot ulcer or infec-
tion; severe cardiac failure, pulmonary
edema, oliguria, anuria, or generalized
edema; polyneuropathy due to causes
other than diabetes; hospitalization due
toDPNwithinthelastmonth;prioruseof
medicationssuchasisoniazid,nitrofuran-
toin, vincristine, and phenytoin; use of
cerebrolysin,-lipoicacid,opiates,trans-
cutaneous electrial nerve stimulation, or
acupuncture within the last month; men-
tal, psychiatric, or other conditions that
may compromise data collection and un-
derstanding of written and verbal infor-
mation given in the trial; present and/or
previous chronic alcohol abuse; and se-
rum creatinine 120 mol/l.
Primary outcome measures
The two coprimary end points were the
TSS and VPT. TSS is a bidimensional
summation of the severity and frequency
ofthefourmainpositiveneuropathicsen-
sory symptoms: pain, burning, paresthe-
sia,andnumbness(8).VPTwasmeasured
using a biothesiometer (Bio-Medical In-
strument Company, Newbury, OH) on
both feet at ﬁve sites: the medial malleo-
lus, medial head of the ﬁrst metatarsal
bone, pulp of the great toe, lateral head of
the ﬁfth metatarsal bone, and tuberosity
of the ﬁfth metatarsal bone. Scores of the
ﬁvemeasurementswereaveragedforeach
foot.Thetwoscoresweretreatedasrepeat
measurements in the statistical model.
TSS and VPT were assessed at screening,
after 5, 10, 15, and 20 infusions, and ev-
ery 4 weeks (5 days) during the oral
treatment period.
Secondary outcome measures
The NIS-LL was assessed on the same
days as the primary end points and was
computed as the sum score of a standard
group of examinations of muscle strength
(0  normal to 4  paralyzed), reﬂexes
(0normalto2absentwithreinforce-
ment), and touch pressure, vibration,
joint position and motion, and pinprick
sensation (0  normal to 2  absent for
each modality) of the great toe and was
scored for both sides of the body (16). All
participating centers were trained by a se-
nior neurologist (I.S.) to adequately per-
form the NIS-LL. Quality of life was
assessed by the short-form (SF)-36 ques-
tionnaire(secondversion)validatedinlo-
cal languages (17) and was completed by
patients at randomization and after the
intravenous and oral treatment periods.
Additional exploratory analyses included
the scores of the four individual TSS
symptoms and three individual compo-
nents of the NIS-LL. In addition, the ef-
fects of alcohol use (categorized as never,
monthly or less, two to four times a
month, two to three times a week, and
four or more times a week) and smoking
habits on treatment were assessed.
Safety parameters
Physical examination and assessment of
vital signs and safety laboratory parame-
terswereperformedatscreeningandafter
the intravenous and oral treatment peri-
ods. Fasting blood glucose was measured
at the same time intervals as the TSS. A1C
was measured at screening, after the infu-
sion period, and after 2 and 5 months of
oral treatment.
Statistical analysis
The two primary outcome measures (TSS
and VPT) were computed as the area un-
der the curve (AUC) averaged over the
time of exposure. The AUC calculations
were performed by the trapezoidal
method. Intermediate missing values
were interpolated linearly in the calcula-
tions. VPT was log transformed. If a pa-
tient dropped out prematurely, the
average was calculated for the exposure
period.Theprimaryanalysisincludedthe
ITT population. To support the primary
analysis, a comparison of the mean
change in the individual outcome mea-
sures from baseline to end of trial in the
two treatment groups was calculated. An
ANCOVA with treatment, center, and in-
sulin treatment stratum as ﬁxed effects
(VPT additionally adjusted for age) and
thebaselineoutcomemeasureasacovari-
ate was used. Based on the linear model,
an F test was used to test the effect of
treatment. The mean difference between
treatments was estimated with a 95% CI
based on the model. Since there were two
primary end points, the Hochberg proce-
dure was applied for multiplicity adjust-
ment(18),ensuringanoverallsigniﬁcance
level of 5%. As a consequence of the
multiplicity adjustment, a signiﬁcant
result(afteradjustment)foreitherofthe
primary end points indicated a positive
study outcome for the given end point.
Possible center interaction was explored
by including an interaction term in the
ANCOVA model as a sensitivity analysis.
Additional supportive analyses included
smoking and alcohol use as separate co-
variates in the ANCOVA.
The power of the trial was required to
be 90%. The sample size consideration
was based on a two-sample t test of the
hypothesisofnomeandifferencebetween
treatments. The sample size calculation
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one point is considered as the minimum
clinicallymeaningfultreatmentdifference
(19). The sample size based on the TSS
was set to 480 patients, with an assumed
SD of 3.1. To compensate for possible
dropouts, the ﬁnal sample size required
was 550 patients. Throughout the statis-
tical analyses, two-sided tests at a signiﬁ-
cance level of 0.05 were used.
RESULTS— A total of 661 patients
were screened and 569 patients were ran-
domized,567ofwhomwereexposedtothe
studymedication(ITTpopulation)and513
of whom completed all assessments in the
study, giving a dropout rate of 9.8%. The
per-protocol population consisted of 506
patients. The ﬂow of the patients through
the trial is shown in the online appendix
(available at http://care.diabetesjournals.
org/cgi/content/full/dc09-0545/DC1). The
demographic and clinical characteristics
of the patients are shown in Table 1. As a
sign of homogeneity, no clinically rele-
vant baseline differences between the
groups were noted for any of the listed
parameters.
The TSS, averaged over the time
course of the trial, was 0.56 points lower
among patients in the actovegin group
compared with the placebo group (95%
CI 0.27–0.85; P  0.0003). When ana-
lyzed from baseline to 160 days, TSS im-
proved by 0.86 points on actovegin
compared with placebo (0.50–1.22; P 
0.001). VPT decreased by 3% in the acto-
vegin group compared with the placebo
group (95% CI 0–6; P  0.08) when av-
eraged over the course of the trial and by
5% after 160 days (1–9; P  0.017).
The mean effect of actovegin upon
TSS scores varied across centers, from
2.93 points (95% CI 4.27 to 1.60)
to 1.19 points (0.67 to 3.04), with evi-
dence of a treatment-by-center interac-
tion (P  0.001). The effect of actovegin
on VPT scores also varied across centers,
from a reduction of 21% (95% CI 9–31)
to an increase of 11% (9 to 35), with
evidenceofatreatment-by-centerinterac-
tion (P  0.02). No differences in the pri-
mary end points were noted between
patients with and without insulin treat-
ment. Furthermore, there was no statisti-
cally signiﬁcant interaction of the
treatmenteffectwithsmokingordrinking
habits (data not shown).
ThemeanvaluesofTSSandVPTdur-
ing the intravenous and oral treatment
phases of the trial are illustrated in Fig. 1.
ArelativelyhighplaceboeffectinTSSwas
observed. The response rate after 160
days, if deﬁned as a clinically meaningful
reduction in TSS of 50%, was 73% in
the actovegin group and 61% in the pla-
cebogroup.Thechangesintheindividual
outcomemeasuresfrombaselinetoendof
treatment in the ITT population are
shown in Table 2. The TSS and its indi-
vidual neuropathic symptoms, as well as
VPT, were reduced signiﬁcantly after 160
days with actovegin treatment than with
placebo (all P  0.05). NIS-LL tended to
improve with actovegin compared with
placeboafter160days(P0.08)because
of signiﬁcantly improved sensory nerve
function (P  0.005) but not muscle
strength (P  0.731) or muscle reﬂexes
(P0.571).Thementalhealthdomainof
SF-36 was signiﬁcantly improved after
160 days of actovegin treatment com-
pared with placebo (P  0.027), whereas
changes in the physical health domain
were not signiﬁcantly different between
groups (P  0.101).
After 160 days, A1C decreased by
0.15  1.48% in the actovegin group
and increased by 0.10  1.65% in the
placebo group (P  0.04 between
groups). Fasting blood glucose decreased
frombaselinetoendofstudyby0.40
2.66 mmol/l in the actovegin group and
by 0.18  2.51 mmol/l in the placebo
group (P  0.19 between groups).
Safety analysis did not reveal any rel-
evant differences in treatment-emergent
AEs (TEAEs) or serious AEs (SAEs) be-
tween groups. There were 186 TEAEs in
92 patients in the actovegin group, while
198 TEAEs occurred in 100 patients in
the placebo group. Of these TEAEs, 41
(22%) and 35 (18%) were considered
possibly or probably related to actovegin
and placebo, respectively. Ten SAEs were
reported in 7 patients during actovegin
treatment, while 11 SAEs occurred in 10
patients treated with placebo. The most
frequent SAEs were cardiac disorders
(seven events in six patients) and infec-
tions (ﬁve events in ﬁve patients). No
deaths occurred during the study.
CONCLUSIONS — The results of
this multicenter, randomized, controlled
clinicaltrialshowthattreatmentofsymp-
tomatic DPN with intravenous infusions
of actovegin (2,000 mg) once daily for 20
days followed by oral administration
(1,800 mg/day) for 140 days improves
neuropathic symptoms as scored by the
TSS, VPT on both feet, the sensory nerve
Table1—Demographic,laboratory,andefﬁcacyparametersintheITTpopulationatbaseline
Actovegin Placebo
n 281 286
Age (years) 55.7  6.4 55.6  6.3
Sex (% male) 31 27
Race (Caucasian/Mongolian) (%) 95/5 93/7
BMI (kg/m
2) 30.6  5.5 30.7  4.8
Systolic blood pressure (mmHg) 134.6  12.5 135.2  12.7
Diastolic blood pressure (mmHg) 81.1  7.3 81.6  7.4
Heart rate (bpm) 74.1  6.4 74.8  6.0
Smoker (%) 10 15
Alcohol drinker (%) 58 53
Insulin treatment (%) 41 41
Duration of diabetes (years) 8.4  6.4 7.9  6.7
Duration of neuropathy (years) 2.9  3.0 2.5  2.8
Retinopathy (%) 26 19
Nephropathy (%) 5 4
Cardiac disorders (%) 41 33
Peripheral artery disease (%) 11 10
Hypertension (%) 79 81
A1C (%) 7.9  1.5 7.7  1.5
Fasting blood glucose (mmol/l) 8.4  2.2 8.3  2.3
TSS 8.3  1.7 8.4  1.6
VPT (volts) 19.7  6.3 20.0  5.8
NIS-LL 8.4  6.5 8.8  7.3
SF-36, physical health 39.8  7.7 39.9  7.5
SF-36, mental health 39.8  11.9 39.9  10.3
Data are means  SD, unless otherwise indicated.
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quality of life as evidenced by the mental
healthdomainoftheSF-36.Thistrialalso
conﬁrmsthefavorablesafetyproﬁleofac-
tovegin, which has been demonstrated in
previous controlled clinical trials (11–14)
and during almost 50 years of postmar-
keting experience.
Themagnitudeofthetreatmenteffect
observed in this trial deserves comment.
A consensus panel previously suggested
that a clinically meaningful difference be-
tween active treatment and placebo for
changes in positive sensory symptoms
from baseline is 0.834 points on a 10-
point scale and 1 point on a scale similar
to the TSS, if an average of several symp-
tom descriptors is used (19). As the mean
difference for the changes in TSS between
actovegin and placebo after 160 days was
0.86 points, we believe that the drug ex-
erted a clinically meaningful effect on the
main neuropathic symptoms.
However,anessentialprerequisitefor
a disease-modifying drug treatment to be
effective is a favorable impact on the nat-
uralprogressionofDPN,whichisprimar-
ily driven by the sensory neuropathic
deﬁcits (impairments) rather than symp-
toms. In this trial, improvement was ob-
served for both neuropathic symptoms
(TSS, pain, paresthesia, and numbness)
andsensorydeﬁcits(VPT,NIS-LLsensory
component), further supporting the no-
Table2—Changesintheindividualoutcomemeasuresfrombaselinetoendoftreatmentinthe
ITT population treated with actovegin or placebo
Actovegin Placebo Difference (95% CI) P
n 281 286
TSS 5.5  2.6 4.7  2.9 0.86 (1.22 to 0.50) 0.0001
Lancinating pain 1.2  1.2 1.0  1.2 0.20 (0.32 to 0.08) 0.0015
Burning pain 1.5  1.1 1.3  1.2 0.26 (0.38 to 0.14) 0.0001
Paresthesia 1.3  1.1 1.2  1.1 0.21 (0.33 to 0.09) 0.0007
Numbness 1.4  1.1 1.2  1.1 0.24 (0.38 to 0.10) 0.0010
VPT (volts) 3.6  4.5 2.9  4.7 5% (9t o1) 0.017
NIS-LL 3.9  4.7 3.7  5.0 0.48 (1.01 to 0.06) 0.080
NIS-LL sensory function 2.1  2.1 1.7  2.1 0.38 (0.64 to 0.12) 0.0045
NIS-LL reﬂexes 0.5  1.3 0.6  1.3 0.05 (0.22 to 0.12) 0.571
NIS-LL muscle strength 1.3  3.1 1.4  3.3 0.06 (0.38 to 0.26 0.731
SF-36, physical health 4.4  7.0 3.6  7.1 0.91 (0.18 to 2.00) 0.101
SF-36, mental health 5.5  10.6 3.8  10.1 1.53 (0.17 to 2.88) 0.027
Data are means  SD, unless otherwise indicated. The ﬁrst two columns represent the raw within-group
differences over time. The last two columns represent model-adjusted between-group differences in the
development over time.
Figure 1—TSS (A) and VPT (B) during treatment with actovegin (n  281) or placebo (n  286).
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cally meaningful. Elevated VPT is an
independent risk factor for the develop-
ment of diabetic foot ulcers. In a 1-year
prospectivemulticenterstudy,thehazard
of the ﬁrst foot ulcer increased by 5.6%
with each volt increase in VPT at baseline
(20). In the present trial, the improve-
ment in VPT from baseline to the end of
the study was signiﬁcantly larger in the
actovegin group compared with the pla-
cebo group (between-group difference:
5% [95% CI 1–9]; P  0.017). With a
baseline mean of 20 volts, the implica-
tion is that VPT improved by 1 volt more
in the actovegin group than the placebo
group. Thus, the observed effect of acto-
veginonVPTappearstoreﬂectaclinically
relevant improvement.
Thisstudyhasseverallimitations.First,
perhaps not surprisingly given that a total
of 26 centers from three countries partic-
ipated in this trial, a center-treatment
interaction effect was noted. Although in-
tensive training was carried out in order
to standardize all relevant procedures, in-
tercenter variations were to be expected.
However, it is reassuring that the ob-
servedtreatmenteffectspersistedafterap-
propriate adjustment for center. Second,
treatment with actovegin was associated
with a slight improvement in A1C levels,
resulting in a mean difference versus pla-
cebo of 0.25%. When adjusting for the
changes in A1C, the treatment effect on
theTSSdecreasedminimallyfrom0.86to
0.83 points. Thus, although the effect of
actovegin on A1C was statistically signif-
icant, as well as potentially beneﬁcial, we
consider the effect size unlikely to intro-
duce bias toward the observed favorable
effect of actovegin on TSS. Third, no ob-
jective peripheral nerve function tests,
such as nerve conduction studies, were
used that could have been more sensitive
to a treatment effect with actovegin than
VPT as a psychophysical measure.
Fourth, a relatively high placebo effect on
the TSS was noted. In the placebo group,
the response rate, if deﬁned as a clinically
meaningful reduction in TSS of 50%,
reached61%.Despitesuchahighplacebo
effect, the corresponding response rate in
the actovegin group of 73% may be con-
sidered clinically relevant, as the relative
advantage of actovegin versus placebo is
20%. A recent meta-analysis (21)
showed that the placebo effect does not
reach a plateau even after 19 weeks of
treatment but tends to continue. Thus,
sustained improvement of symptoms,
such as pain in the placebo group with
increasing duration of the trial, renders it
difﬁcult to show superiority of the active
drug over placebo.
The mechanisms by which actovegin
exerts its effect on neuropathic symptoms
is not clear, but it has been shown to im-
prove the cellular energy level, enhance
glucose uptake and metabolism, and to
increase oxygen absorption and utiliza-
tion (9–11). Dose-dependent effects on
oxygenabsorptionhavebeenshowntobe
related to an increased synthesis of high-
energy phosphates (9). Actovegin pro-
motesoxidativemetabolismandshiftsthe
redox-balance of the cells into the direc-
tionofoxidizedsubstrates.Thisalsoleads
to an increased availability of energy-rich
phosphates, such as ATP and creatine
phosphate. Furthermore, actovegin may
protect against hypoxic cell injury (22),
whichalsocouldexplainitseffect,since
reduced endoneurial blood ﬂow and
nerve ischemia are thought to play a
major pathogenetic role in DPN (6).
Moreover, recent in vitro studies using
freshly prepared primary rat neurons
showed that actovegin increases the cell
number, neurite length, and the num-
ber of synaptic connections of neurons
in a dose-dependent manner and inhib-
its apoptosis as measured by caspase-3
activity (M. Elmlinger et al., unpub-
lished observations).
Actovegin contains inositolphospho-
oligosaccharides (IPOs) integrated in the
cell membrane, which activate glucose
transport (23). IPOs can contribute to up
to 50% of the maximum insulin effect on
glucose transport (10) and also stimulate
the activity of certain enzymes including
pyruvatedehydrogenase(24),thekeyen-
zyme of the citric acid cycle. IPOs are re-
leased from liver membranes upon
insulinstimulation(22)andmimicawide
spectrum of insulin-like activities in vari-
ous cells due to their soluble nature and
widespread distribution (25). Thus, there
is direct and indirect evidence to support
the notion that actovegin exerts an insu-
lin-like effect leading to enhancement of
glucoseutilizationwithadirectimpacton
the cellular metabolism and energy bal-
ance in distinct cellular systems.
In conclusion, treatment with actove-
gin intravenously for 20 days and subse-
quentoraltreatmentfor140dayswassafe
and effective in improving neuropathic
symptoms, VPT, sensory nerve function,
and mental health in type 2 diabetic pa-
tients with symptomatic polyneuropathy.
The mechanisms by which actovegin ex-
erts these favorable effects on nerve func-
tion remain to be established.
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